Published in Transplantation on February 15, 2006
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Regulatory T cells in transplantation tolerance. Nat Rev Immunol (2003) 6.42
Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med (2003) 4.12
Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med (1990) 3.73
Antigen localization and migration in immunity and tolerance. N Engl J Med (1998) 3.71
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Banff schema for grading liver allograft rejection: an international consensus document. Hepatology (1997) 3.22
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
Transplantation tolerance from a historical perspective. Nat Rev Immunol (2001) 2.04
Immunity or tolerance: opposite outcomes of microchimerism from skin grafts. Nat Med (2001) 1.93
Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78
Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol (1997) 1.41
Chimerism and transplantation tolerance: cause and effect. Immunol Today (1996) 1.35
The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat. Nat Med (1999) 1.35
Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation (1995) 1.32
Engraftment assessment in human and mouse liver tissue after sex-mismatched liver cell transplantation by real-time quantitative PCR for Y chromosome sequences. Liver Transpl (2002) 1.27
Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. Transplantation (1998) 1.22
Redistribution of renal allograft-responding leukocytes during rejection. II. Kinetics and specificity. J Exp Med (1982) 1.21
Organ graft tolerance: the liver effect. Lancet (1994) 1.14
Development, stability, and clinical correlations of allogeneic microchimerism after solid organ transplantation. Transplantation (1996) 1.08
Donor and recipient leukocytes in organ allografts of recipients with variable donor-specific tolerance: with particular reference to chronic rejection. Liver Transpl (2000) 1.07
Donor hematopoietic progenitor cells in nonmyeloablated rat recipients of allogeneic bone marrow and liver grafts. Transplantation (1999) 1.04
Exploiting tolerance processes in transplantation. Science (2004) 1.02
Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res (2001) 0.91
A monoclonal antibody (L21-6) recognizing an invariant chain expressed on the cell surface in rats with the exception of the BN (RT1n): a study of tissue and strain distributions. Transplant Proc (1995) 0.91
A comparison between real-time quantitative PCR and DNA hybridization for quantitation of male DNA following myoblast transplantation. Cell Transplant (2004) 0.83
Peripheral blood microchimerism in human liver and renal transplant recipients: rejection despite donor-specific chimerism. Transplantation (1997) 0.83
Transplantation of the bone marrow microenvironment leads to hematopoietic chimerism without cytoreductive conditioning. Transplantation (2000) 0.82
Microchimerism in sensitized renal patients. Transplantation (1999) 0.78
Persistence of stable intragraft cell chimerism in rat liver allografts after drug-induced tolerance. Transplantation (2001) 0.77
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Production of alpha 1,3-galactosyltransferase-deficient pigs. Science (2002) 3.96
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
Generation of cloned transgenic pigs rich in omega-3 fatty acids. Nat Biotechnol (2006) 3.07
Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol (2005) 2.78
Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J Exp Med (2006) 2.77
Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med (2005) 2.67
Oral hydrogen water prevents chronic allograft nephropathy in rats. Kidney Int (2009) 2.35
VENO-VENOUS BYPASS WITHOUT SYSTEMIC ANTICOAGULATION IN CANINE AND HUMAN LIVER TRANSPLANTATION. Surg Forum (1983) 2.30
THE USE OF COMBINED PRESERVATION TECHNIQUES FOR EXTENDED STORAGE OF ORTHOTOPIC LIVER HOMOGRAFTS. Surg Gynecol Obstet (1968) 2.20
Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology (2006) 2.08
A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl (2002) 2.07
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med (2005) 1.75
Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74
Complications of right lobe living donor liver transplantation. J Hepatol (2009) 1.73
Recent advances in hydrogen research as a therapeutic medical gas. Free Radic Res (2010) 1.65
Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61
A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. Blood (2011) 1.60
EFFECT OF CYCLOSPORIN ON HEPATIC REGENERATION. Surg Forum (1986) 1.59
Long-term survival, nutritional autonomy, and quality of life after intestinal and multivisceral transplantation. Ann Surg (2012) 1.59
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood (2011) 1.55
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology (2002) 1.54
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Biliverdin administration protects against endotoxin-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol (2005) 1.49
Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4⁺ effector memory T cells. Eur J Immunol (2011) 1.49
Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant (2006) 1.48
The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients. Transplantation (2009) 1.47
Carbon monoxide inhalation protects rat intestinal grafts from ischemia/reperfusion injury. Am J Pathol (2003) 1.47
Functionally important glycosyltransferase gain and loss during catarrhine primate emergence. Proc Natl Acad Sci U S A (2006) 1.46
Hydrogen-supplemented drinking water protects cardiac allografts from inflammation-associated deterioration. Transpl Int (2012) 1.44
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
Transplantation of en bloc pediatric kidneys when the proximal vascular cuff is too short. Transplantation (2007) 1.42
Adenosine injection prior to cardioplegia enhances preservation of senescent hearts in rat heterotopic heart transplantation. Eur J Cardiothorac Surg (2012) 1.42
Profiling molecular changes induced by hydrogen treatment of lung allografts prior to procurement. Biochem Biophys Res Commun (2012) 1.42
Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology (2004) 1.39
SUCCESSFUL ORTHOTOPIC TRANSPLANTATION OF LIVER HOMOGRAFTS AFTER EIGHT TO TWENTY-FIVE HOURS PRESERVATION. Surg Forum (1967) 1.37
Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am J Transplant (2005) 1.36
Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr (2006) 1.36
MELD and prediction of post-liver transplantation survival. Liver Transpl (2006) 1.33
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA (2012) 1.33
Protection of transplant-induced renal ischemia-reperfusion injury with carbon monoxide. Am J Physiol Renal Physiol (2004) 1.33
Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab Invest (2008) 1.32
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Caveolin-1 expression by means of p38beta mitogen-activated protein kinase mediates the antiproliferative effect of carbon monoxide. Proc Natl Acad Sci U S A (2005) 1.29
A mouse model of accelerated liver aging caused by a defect in DNA repair. Hepatology (2012) 1.29
Wnt'er in liver: expression of Wnt and frizzled genes in mouse. Hepatology (2007) 1.27
Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood (2008) 1.27
Clinical islet xenotransplantation: how close are we? Diabetes (2012) 1.26
Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology (2006) 1.24
Origin of lymph node-derived lymphocytes in human hepatic allografts. Clin Transpl (1989) 1.24
IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol (2008) 1.22
Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann Surg (2009) 1.21
Toll-like receptor 4 mediates the early inflammatory response after cold ischemia/reperfusion. Transplantation (2007) 1.21
The transcription factor interferon regulatory factor-1 mediates liver damage during ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol (2006) 1.21
Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology (2002) 1.21
Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci (2002) 1.20
Ethyl pyruvate ameliorates liver ischemia-reperfusion injury by decreasing hepatic necrosis and apoptosis. Transplantation (2005) 1.19
Role of NF-kappaB on liver cold ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol (2002) 1.19
Protective effect of carbon monoxide in transplantation. J Cell Mol Med (2006) 1.19
Molecular basis of evolutionary loss of the alpha 1,3-galactosyltransferase gene in higher primates. J Biol Chem (2001) 1.18
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation (2003) 1.18
Mechanisms of Toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart. Transplantation (2009) 1.17
Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res (2008) 1.16
Inhaled hydrogen gas therapy for prevention of lung transplant-induced ischemia/reperfusion injury in rats. Transplantation (2010) 1.14
Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology (2009) 1.13
Histologic graft assessment after clinical islet transplantation. Transplantation (2009) 1.12
Characterization of transplanted green fluorescent protein+ bone marrow cells into adipose tissue. Stem Cells (2007) 1.12
OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant (1991) 1.11
Poor allostimulatory function of liver plasmacytoid DC is associated with pro-apoptotic activity, dependent on regulatory T cells. J Hepatol (2008) 1.10
Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg (2005) 1.10
NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol (2010) 1.09